Neuroendocrine Prostate Cancer

• CLINICAL_TRIALS research · 2026-04-01
  Clinical Trial Update: A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1) [Phase 1]

  Phase 1 first-in-human study of ML261, an autologous DLL3-targeted CAR T cell therapy, in relapsed/refractory small cell lung cancer and sel…

• CLINICAL_TRIALS research · 2026-03-24
  Clinical Trial Update: Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors [Phase 1]

  Phase I study of [225Ac]Ac-ETN029 for DLL3-expressing advanced solid tumors is currently recruiting, sponsored by Novartis Pharmaceuticals.

• CLINICAL_TRIALS research · 2026-03-11
  Clinical Trial Update: NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. [Phase 1]

  This phase 1 exploratory study evaluates the safety and potential efficacy of a PSMA, SSTR2, and GRPR-targeted radioligand therapy in metast…

• CLINICAL_TRIALS research · 2025-11-19
  Clinical Trial Update: Memantine Hydrochloride in Prostate Cancer Patients [Phase 2]

  A Phase 2 clinical trial evaluating memantine hydrochloride in metastatic castration-resistant prostate cancer and other prostate cancers, c…

• CLINICAL_TRIALS research · 2025-09-23
  Clinical Trial Update: A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) [Phase 1, Phase 2]

  Phase 1/2 SKYBRIDGE study evaluating Peluntamig (PT217) in DLL3-expressing neuroendocrine carcinomas; currently recruiting.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• CLINICAL_TRIALS research · 2025-06-17
  Clinical Trial Update: Study of ZG006 in Participants With Neuroendocrine Prostate Cancer [Phase 2]

  Phase 2 clinical trial evaluating ZG006 for neuroendocrine prostate cancer; the study is not yet recruiting.